Physician profile
Wendy R Sharp
NPI 1043537509
$1,326.02
in general payments reported to CMS, 2019-2025
21 companies · $511 in 2025
The $511 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $150 · 2023: $177 · 2024: $336 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $275.67 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Tris Pharma INC | $228.05 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Novo Nordisk INC | $217.60 | 2022-2025 | Ozempic |
| Glaxosmithkline, LLC. | $114.22 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $90.61 | 2021-2025 | Mounjaro |
| Abbvie INC. | $87.17 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.72 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $31.52 | 2022 | |
| Merck Sharp & Dohme LLC | $30.74 | 2022-2024 | Vaxneuvance, Vaxelis, Gardasil |
| Pfizer INC. | $28.19 | 2024 | |
| Abbott Laboratories | $24.62 | 2022 | |
| Hologic Sales and Service, LLC | $21.45 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.74 | 2021 | |
| Adlon Therapeutics L.P. | $17.00 | 2021 | |
| Exact Sciences Corporation | $16.84 | 2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.44 | 2021 | |
| Astellas Pharma US INC | $15.25 | 2024 | Veozah |
| Cranial Technologies, INC | $14.65 | 2023 | Doc Band |
| Seqirus USA INC | $13.08 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2022 | |
| Tactile Systems Technology INC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.